Table 4 Effects of the de-implementation strategy, measurement, and covariates on the outcome “use of EPO” in EPO eligible patients (Hb <13 g/dL)
OR | 95% CI | p value | |
|---|---|---|---|
Intervention group, relative to control group | 1.3 | 0.3 to 6.8 | 0.73 |
Time effect, effect measurement relative baseline | 0.3 | 0.1 to 0.9 | 0.043 |
Joint, knee relative to hip | 0.9 | 0.6 to 1.3 | 0.60 |
Sex, female relative to male | 1.2 | 0.7 to 2.1 | 0.50 |
ASA classification, relative to 1 | |||
• ASA 2 | 1.0 | 0.5 to 1.7 | 0.88 |
• ASA 3–4 | 0.5 | 0.3 to 1.1 | 0.07 |
BMI | 1.0 | 1.0 to 1.0 | 0.42 |
Preoperative Hb | 0.3 | 0.2 to 0.4 | <0001 |
Age | 1.0 | 1.0 to 1.0 | 0.97 |